Source: Antioxidants & Redox Signaling. Unidade: ICB
Subjects: FARMACOLOGIA, ANALGÉSICOS, INFLAMAÇÃO, DOR, ÚLCERA GÁSTRICA, SISTEMA GASTROINTESTINAL, ANTI-INFLAMATÓRIOS NÃO ESTEROIDES, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Soraia Katia Pereira et al. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxidants & Redox Signaling, p. 7 , 2020Tradução . . Disponível em: https://doi.org/10.1089/ars.2019.7884. Acesso em: 14 nov. 2024.APA
Costa, S. K. P., Allain, T., Dallazen, J. L., Santos, L. G., Buret, A. G., Vaughan, D. J., et al. (2020). Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxidants & Redox Signaling, 7 . doi:10.1089/ars.2019.7884NLM
Costa SKP, Allain T, Dallazen JL, Santos LG, Buret AG, Vaughan DJ, Fowler CJ, De Nucci G, Wallace JL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids [Internet]. Antioxidants & Redox Signaling. 2020 ;7 .[citado 2024 nov. 14 ] Available from: https://doi.org/10.1089/ars.2019.7884Vancouver
Costa SKP, Allain T, Dallazen JL, Santos LG, Buret AG, Vaughan DJ, Fowler CJ, De Nucci G, Wallace JL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids [Internet]. Antioxidants & Redox Signaling. 2020 ;7 .[citado 2024 nov. 14 ] Available from: https://doi.org/10.1089/ars.2019.7884